Mesoblast (MESO) Exchange Rate Effect (2014 - 2024)
Mesoblast (MESO) posted Exchange Rate Effect of $24000.0 for Q2 2023, up 142.86% sequentially from -$56000.0 in Q1 2023, and up 115.38% YoY from $11142.9 in Q2 2022.
Powered by 
Analysis
Mesoblast (MESO) Exchange Rate Effect (2014 - 2024) Analysis & Trends
Mesoblast has reported Exchange Rate Effect for 8 years, with the latest figure at $24000.0 in Q2 2023.
- Quarterly Exchange Rate Effect rose 115.38% year-over-year to $24000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$168000.0 (up 69.45% YoY) and the FY2025 annual result came in at $1.1 million, up 2080.0% from the prior year.
- Exchange Rate Effect grew to $24000.0 in Q2 2023 per MESO's latest filing, from -$56000.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $1.8 million in Q2 2020 and troughed at -$753000.0 in Q3 2022.
- A 5-year average of $122611.1 and a median of $3000.0 in 2021 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2020 and 2022: Exchange Rate Effect surged 4352.38% in 2020, then plunged 7700.0% in 2022.
- Over 5 years, Exchange Rate Effect stood at $371000.0 in 2019, then jumped by 206.2% to $1.1 million in 2020, then plunged by 93.4% to $75000.0 in 2021, then surged by 722.67% to $617000.0 in 2022, then sank by 96.11% to $24000.0 in 2023.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered $24000.0, -$56000.0, and $617000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 78,000.00 |
| Jun 30, 2023 | 62,000.00 |
| Mar 31, 2023 | -385,000.00 |
| Dec 31, 2022 | -311,000.00 |
| Sep 30, 2022 | 504,000.00 |
| Jun 30, 2022 | -156,000.00 |
| Mar 31, 2022 | 8,000.00 |
| Dec 31, 2021 | 75,000.00 |
| Sep 30, 2021 | 122,000.00 |
| Jun 30, 2021 | -2,000.00 |
| Mar 31, 2021 | -220,000.00 |
| Dec 31, 2020 | 1.14 Mn |
| Sep 30, 2020 | 501,000.00 |
| Mar 31, 2020 | -290,000.00 |
| Dec 31, 2019 | 328,000.00 |
| Sep 30, 2019 | -43,000.00 |
| Mar 31, 2019 | 56,000.00 |
| Dec 31, 2018 | -126,000.00 |
| Sep 30, 2018 | -143,000.00 |
| Jun 30, 2018 | -139,000.00 |